<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28154" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Quinidine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Ashish</given-names>
          </name>
          <aff>Conemaugh Memorial Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>SISODIA</surname>
            <given-names>JITENDRA</given-names>
          </name>
          <aff>M.S University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashish Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>JITENDRA SISODIA declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28154.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Quinidine, a stereoisomer of quinine,&#x000a0;is derived from the bark of the South American cinchona tree. Quinidine is regarded as&#x000a0;one of the earliest known antiarrhythmics, and it serves as a&#x000a0;class 1a antiarrhythmic drug and an antimalarial agent. An interprofessional approach involving specialties such as cardiology, rheumatology, infectious disease, intensive care, and nursing is necessary when using this drug. Quinidine is a medication primarily utilized to manage and treat specific arrhythmias and malaria in patients. This activity reviews quinidine's indications, actions, and contraindications, emphasizing its significance as a valuable agent for treating certain arrhythmias and malaria. In addition, this activity will focus on elucidating the mechanism of action, adverse event profile, and other crucial factors, including pharmacokinetics, monitoring, and relevant interactions pertinent for interprofessional healthcare teams to effectively manage conditions related to arrhythmia and malaria in patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the pharmacological properties and mechanisms of action of quinidine as a Class 1a antiarrhythmic and antimalarial agent.</p></list-item><list-item><p>Screen patients with arrhythmias to identify suitable candidates for quinidine therapy based on their medical history, EKG findings, and overall health status.</p></list-item><list-item><p>Integrate quinidine into treatment plans for patients with specific arrhythmias, ensuring proper dosing, administration, and monitoring.</p></list-item><list-item><p>Communicate with patients about the benefits, risks, and potential adverse effects of quinidine treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28154&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28154">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28154.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Quinidine, a stereoisomer of quinine,&#x000a0;is derived from the bark of the South American cinchona tree. Quinidine serves as a&#x000a0;class 1a antiarrhythmic drug and an antimalarial agent. Quinidine is a medication mainly used for treating and managing arrhythmias in patients.<xref ref-type="bibr" rid="article-28154.r1">[1]</xref>&#x000a0;</p>
        <p>Quinidine is approved by theU.S. Food and Drug Administration (FDA) for the treatment of the indications listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Plasmodium falciparum</italic>&#x000a0;malaria: Quinidine is recognized as an effective treatment for severe and complicated malaria, either as a standalone therapy or combined with an exchange transfusion.<xref ref-type="bibr" rid="article-28154.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Atrial fibrillation/flutter to sinus rhythm conversion</p>
          </list-item>
          <list-item>
            <p>Reduction of frequency of atrial fibrillation/flutter relapse</p>
          </list-item>
          <list-item>
            <p>Ventricular arrhythmia suppression</p>
          </list-item>
          <list-item>
            <p>Pseudobulbar affect:&#x000a0;The FDA approved the combination of dextromethorphan and quinidine capsules to treat the pseudobulbar affect.<xref ref-type="bibr" rid="article-28154.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>Quinidine is currently under investigation for its potential role in managing KCNT1 (potassium sodium-activated channel subfamily T member 1)-related epileptic disorders, and it has already received FDA approval for this indication.<xref ref-type="bibr" rid="article-28154.r4">[4]</xref></p>
      </sec>
      <sec id="article-28154.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Quinidine is used as an antiarrhythmic agent and an antimalarial agent. The mechanism of action varies depending on the indication.&#x000a0;</p>
        <p>Like other class 1a antiarrhythmic agents, quinidine inhibits the fast inward sodium current, leading to a depression of phase 0 of the action potential. This mechanism dampens the excitability of cardiac muscles, ultimately resulting in the prolongation of the action potential duration and a decrease in automaticity. Quinidine exhibits a "use-dependent block" effect on the fast inward sodium current, which implies that the drug's impact increases during higher heart rates and decreases during lower heart rates.<xref ref-type="bibr" rid="article-28154.r5">[5]</xref></p>
        <p>Quinidine also reduces potassium efflux during repolarization, inhibiting the slow, delayed rectifier potassium current. Furthermore, it displays a pattern of "reverse-use dependence," resulting in less current suppression at more frequent depolarizations. In addition, quinidine impacts calcium transport across cell membranes. These combined effects contribute to the prolongation of the QRS interval.<xref ref-type="bibr" rid="article-28154.r6">[6]</xref><bold>&#x000a0;</bold></p>
        <p>Quinidine exerts a parasympatholytic effect, resulting in an increase in sinus rate. In addition, it prolongs the QRS complex and the QTc interval while having a negligible effect on the PR interval.<xref ref-type="bibr" rid="article-28154.r6">[6]</xref><xref ref-type="bibr" rid="article-28154.r7">[7]</xref></p>
        <p>Quinidine functions as an effective antimalarial agent by targeting the erythrocytic stage of the&#x000a0;<italic toggle="yes">Plasmodium</italic> species. The drug&#x000a0;achieves this by accumulating&#x000a0;within the parasite's food vacuole and forming a complex with heme, thereby inhibiting crystallization within the same compartment. Consequently, the inhibited heme polymerase activity leads to the accumulation of cytotoxic-free heme. Moreover, quinidine exhibits anticholinergic activity as an additional pharmacological feature.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Absorption: Quinidine exhibits a time-to-peak plasma concentration of approximately 2 hours, whereas the extended-release versions typically take 3 to 4 hours to reach peak levels. Notably, sustained-release quinidine gluconate has been found to yield higher serum concentrations than sustained-release quinidine sulfate.</p>
          </list-item>
          <list-item>
            <p>Distribution: Quinidine shows a substantial volume of distribution (2 to 3 L/kg), with an increased volume in individuals with cirrhosis and a decreased volume in individuals with congestive heart failure (CHF).&#x000a0;This medication primarily binds to alpha-1 acid glycoprotein, which increases when the body is under stress. This process leads to elevated serum levels of total quinidine during acute myocardial infarction. However, the drug's unbound (active) form may remain within the normal range. In addition, quinidine achieves higher concentrations in the heart, liver, and kidneys.</p>
          </list-item>
          <list-item>
            <p>Metabolism: Quinidine undergoes hepatic metabolism primarily through hydroxylation reactions mediated by cytochrome P450 enzymes (60% to 80%). These reactions form active compounds, notably the essential antiarrhythmic agent 3-hydroxy-quinidine (3HQ). Adjusting the medication dosage is necessary in cases of hepatic impairment to ensure optimal treatment outcomes.</p>
          </list-item>
          <list-item>
            <p>Excretion: The elimination half-life of quinidine increases with age and in conditions such as cirrhosis and CHF. Less than 20% of the drug is excreted unchanged in the urine, and dosage adjustment may be required only in cases of severe renal impairment.<xref ref-type="bibr" rid="article-28154.r8">[8]</xref><xref ref-type="bibr" rid="article-28154.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28154.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Quinidine is available in both parenteral and oral formulations.</p>
        <p>
<bold>Dosage</bold>
</p>
        <p>Parenteral: Quinidine&#x000a0;is available as an injectable dose administered via the intravenous (IV) route in its gluconate preparations.</p>
        <p>Oral: Quinidine tablets are available in both immediate-release and extended-release formulations. Immediate-release formulations are available in tablets of 200 and 300 mg (quinidine sulfate salt). Each 200 mg tablet contains 166 mg of quinidine base, and each 300 mg tablet contains 249 mg of quinidine base. The extended-release preparations are available in 324 mg (quinidine gluconate salt) tablets, with each tablet equivalent to 202 mg of quinidine base.&#x000a0;The patients using the extended-release preparations are advised to swallow the whole pill without chewing, crushing, or breaking the tablet.&#x000a0;</p>
        <p>
<bold>Dosage Regimens</bold>
</p>
        <p>Atrial fibrillation/atrial flutter to sinus rhythm conversion: The dosage regimens for atrial&#x000a0;fibrillation/atrial&#x000a0;flutter to&#x000a0;sinus&#x000a0;rhythm&#x000a0;conversion are available in 2 formulations as listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral immediate-release formulation: The initial therapy involves administering 2 tablets of 200 mg each every&#x000a0;6 hours to the patients. The dose may be cautiously increased if the desired pharmacological conversion is not achieved after 4 to 5 doses.</p>
          </list-item>
          <list-item>
            <p>Oral extended-release formulation: For the first&#x000a0;treatment&#x000a0;option, patients are administered 2 tablets of&#x000a0;324 mg each (equivalent to 403 mg of quinidine base) every 8 hours. If the desired pharmacological conversion is not achieved after 3 or 4 doses, the dose may be increased cautiously. As an alternative regimen, patients may have been prescribed 1 tablet (equivalent to 202 mg of quinidine base) every 8 hours for 2 days, followed by 2 tablets (equivalent to 403 mg of quinidine base) every 12 hours for 2 days, and, finally, 2 tablets (equivalent to 403 mg of quinidine base) every 8 hours for up to 4 days. For the final 4-day treatment plan, the lower dose may be opted at the physician's discretion.</p>
          </list-item>
        </list>
        <p>During any of these regimens, if at any time the QRS complex or QTC interval widens to 130% of its pre-treatment duration, the QTC interval is longer than 500 ms, P waves disappear, or the patient experiences significant tachycardia, bradycardia, or hypotension, the quinidine therapy should be discontinued immediately.</p>
        <p>Reduction of atrial fibrillation/flutter relapse:&#x000a0;The dosage regimens for&#x000a0;reduction of atrial fibrillation/flutter relapse are available in 2 formulations as listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral immediate-release formulation: The initial therapy involves administering 1 tablet (equivalent to 166 mg of quinidine base) every 6 hours. If the regimen is well tolerated and the serum quinidine level remains within the therapeutic index range, the dose may be cautiously increased to achieve the desired pharmacological effect.</p>
          </list-item>
          <list-item>
            <p>Oral extended-release formulation:&#x000a0;Patients may have been administered 1 tablet&#x000a0;(equivalent to 202&#x000a0;mg of quinidine base) every 8 or 12 hours for the first treatment option. If the regimen is well-tolerated and the serum quinidine level remains within the therapeutic index range, the dose may be cautiously increased to achieve the desired pharmacological effect.</p>
          </list-item>
        </list>
        <p>During any of these regimens, if at any time the QRS complex or QTC interval widens to 130% of its pre-treatment duration, the QTC interval is longer than 500 ms, P waves disappear, or the patient experiences significant tachycardia, bradycardia, or hypotension, the total daily dose of quinidine should be reduced.</p>
        <p>Ventricular arrhythmias&#x000a0;suppression: The dosage regimens for ventricular arrhythmias&#x000a0;suppression have not been extensively studied. However, these regimens have typically been similar to those described above for treating atrial fibrillation. Therefore, this therapy should be carefully managed and optimized based on the results obtained from programmed electrical stimulation or Holter monitoring, whenever possible, along with exercise testing.</p>
        <p>Brugada syndrome&#x000a0;and&#x000a0;short QT syndrome:&#x000a0;In the management of ventricular arrhythmias associated with Brugada syndrome and short QT syndrome, the American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guidelines recommend administering an IV loading dose of 800 mg in 50 mL at a rate of 50 mg/min.<xref ref-type="bibr" rid="article-28154.r6">[6]</xref></p>
        <p>Pseudobulbar affect: The initial treatment involves administering a fixed dose combination of 10 mg quinidine sulfate and 20 mg dextromethorphan once daily for 7 days. Subsequently, the daily dose is increased to 1 capsule every 12 hours.<xref ref-type="bibr" rid="article-28154.r3">[3]</xref></p>
        <p>Treatment of&#x000a0;<italic toggle="yes">P falciparum</italic>&#x000a0;malaria: According to the manufacturer label, the dosage regimen for quinidine sulfate tablets should be similar to&#x000a0;the regimen described in the package insert of quinidine gluconate injection. Notably,&#x000a0;a few years ago, the sole manufacturer of quinidine IV products discontinued this product in the United States.<xref ref-type="bibr" rid="article-28154.r2">[2]</xref></p>
        <p>
<bold>Specific Patient Population&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patient with hepatic impairment: The manufacturer label does not provide specific dosage adjustment guidance for patients with hepatic impairment. However, as most quinidine is metabolized and eliminated via cytochrome 3A4, caution should be exercised when using the drug in these patients.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patient with renal impairment: The manufacturer label does not offer dosage adjustment guidance for patients with renal impairment. However, as 20% of quinidine is eliminated in the urine, the drug should be used with caution in these patients, and a lower dose may be necessary, especially in patients with severe renal impairment.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pregnant considerations:&#x000a0;The FDA previously categorized quinidine&#x000a0;as a medication belonging to pregnancy category C. Both quinidine and its metabolites have the potential to cross the placental membrane and be detected in the neonatal serum. As such, caution should be exercised when prescribing quinidine to pregnant individuals.</p>
          </list-item>
          <list-item>
            <p>Breastfeeding considerations:&#x000a0;To ensure the safety of nursing mothers, the manufacturer advises against quinidine therapy due to the presence of quinidine in breast milk.<xref ref-type="bibr" rid="article-28154.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Pediatric patients: The safety and efficacy of quinidine for antiarrhythmic use have not been established in the pediatric patient population.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Geriatric patients: The safety and efficacy of quinidine have not been systematically studied in this patient population.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28154.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Although quinidine is effective in managing specific conditions, the drug is associated with various adverse effects affecting bodily systems, as listed below.</p>
        <p>Cardiovascular: Quinidine is widely recognized as one of the most common drugs that cause a prolongation of the QT interval. In some cases, this prolonged QT interval may progress to pleomorphic tachyarrhythmia, known as torsades de pointes (TdP), affecting approximately 1% to 3% of patients. Cardiac adverse effects are more likely to occur in patients with lower heart rates and hypokalemia. The QT interval prolongation is more pronounced in females than males, and the onset of severe QT prolongation may indicate drug toxicity. Palpitations, angina pectoris, new or worsened cardiac arrhythmia, and syncope are all possible signs of these cardiovascular effects.<xref ref-type="bibr" rid="article-28154.r10">[10]</xref><xref ref-type="bibr" rid="article-28154.r11">[11]</xref></p>
        <p>Central nervous system: Quinidine crosses the blood-brain barrier through passive diffusion and an active transport system, potentially leading to adverse effects such as dizziness, fatigue, headache, disturbed sleep, nervousness, and ataxia.<xref ref-type="bibr" rid="article-28154.r12">[12]</xref></p>
        <p>Dermatological: Quinidine use has been associated with the occurrence of skin rash.<xref ref-type="bibr" rid="article-28154.r13">[13]</xref></p>
        <p>Gastrointestinal: Quinidine use has been linked to potential adverse effects such as hepatotoxicity, diarrhea, digestive distress, nausea and vomiting, and esophagitis.<xref ref-type="bibr" rid="article-28154.r13">[13]</xref></p>
        <p>Neuromuscular&#x000a0;and skeletal: Quinidine use may lead to neuromuscular and skeletal effects, including weakness and tremors.<xref ref-type="bibr" rid="article-28154.r14">[14]</xref></p>
        <p>Ophthalmological: Quinidine use has been associated with potential visual disturbances.<xref ref-type="bibr" rid="article-28154.r15">[15]</xref></p>
        <p>Other adverse effects of quinidine&#x000a0;are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Fever and hypersensitivity reactions occur in individuals who are allergic to the drug.</p>
          </list-item>
          <list-item>
            <p>Hypokalemia or hypomagnesemia can potentially lead to drug toxicity when taking quinidine.</p>
          </list-item>
          <list-item>
            <p>Hemolysis is a possible occurrence in patients with G6PD deficiencies when using quinidine.</p>
          </list-item>
          <list-item>
            <p>Cinchonism, which is associated with quinidine as it is a stereoisomer of quinine derived from the bark of the cinchona tree, can manifest with symptoms such as tinnitus, sensorineural hearing loss, blurring of vision, diplopia, photophobia, confusion, headache, delirium, and decreased hearing to profound deafness.</p>
          </list-item>
          <list-item>
            <p>Quinidine use may rarely lead to drug-induced lupus erythematosus (DILE).<xref ref-type="bibr" rid="article-28154.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Quinidine use has been associated with the development of Sjogren's syndrome.</p>
          </list-item>
          <list-item>
            <p>Blackwater fever, a condition linked to quinidine, is characterized by a triad of massive hemolysis, hemoglobinemia, and hemoglobinuria, potentially leading to acute kidney injury, jaundice, and, in severe cases, even death.<xref ref-type="bibr" rid="article-28154.r2">[2]</xref><xref ref-type="bibr" rid="article-28154.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Quinidine is an inhibitor of CYP450 enzymes and has the potential to interact with drugs that are metabolized by this enzyme system.</p>
          </list-item>
          <list-item>
            <p>Quinidine has been demonstrated to reduce digoxin's total clearance by 30%, renal clearance by 32%, and nonrenal clearance by 29%.<xref ref-type="bibr" rid="article-28154.r18">[18]</xref>&#x000a0;This action is explained by quinidine's property of displacing digoxin from protein-binding sites, which can result in altered clearance. Furthermore, the reduction in renal clearance may be attributed to quinidine's inhibition of the renal secretion of digoxin.<xref ref-type="bibr" rid="article-28154.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Erythromycin has been demonstrated to decrease quinidine clearance, leading to increased serum concentrations and potentially predisposing patients to quinidine toxicity. Therefore, when administering erythromycin concurrently with quinidine, it is advisable to monitor patients' serum potassium and magnesium levels and perform timely electrocardiograms (EKGs) to detect any signs of possible toxicity.<xref ref-type="bibr" rid="article-28154.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Phenobarbital and phenytoin have been demonstrated to reduce the half-life of quinidine by half, potentially by increasing its metabolism through the induction of CYP450 enzymes.<xref ref-type="bibr" rid="article-28154.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Cimetidine competes for the renal tubular secretion of quinidine in both its unchanged form and metabolites, leading to increased quinidine concentration in the plasma.<xref ref-type="bibr" rid="article-28154.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>QT-prolonging drugs, such as clarithromycin and amiodarone, increase TdP risk when administered with quinidine.<xref ref-type="bibr" rid="article-28154.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28154.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The contraindications of quinidine include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenic purpura</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to quinine, mefloquine, quinidine, or any component used in the drug preparation.</p>
          </list-item>
          <list-item>
            <p>Heart block greater than first degree.</p>
          </list-item>
          <list-item>
            <p>Concurrent use with amprenavir, cisapride, ritonavir, fluoroquinolones, or other drugs known to prolong the QT interval</p>
          </list-item>
          <list-item>
            <p>Congenital long QT interval</p>
          </list-item>
          <list-item>
            <p>AV block, as concurrent use of the drug can progress to a complete heart block&#x000a0;<xref ref-type="bibr" rid="article-28154.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients on digoxin may experience higher plasma quinidine levels and a shorter half-life on low doses than those not taking quinidine.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pediatric patients typically require a higher dose of quinidine compared to adults.<xref ref-type="bibr" rid="article-28154.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>The advanced-age population exhibits reduced clearance of quinidine and an increased drug half-life, potentially leading to an increased risk of toxicity. Therefore, appropriate adjustment of drug dosages is necessary for this age group.<xref ref-type="bibr" rid="article-28154.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>In patients with CHF, dosage adjustment of quinidine is recommended, as regular drug dosing may result in abnormally high serum concentrations.<xref ref-type="bibr" rid="article-28154.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Quinidine&#x000a0;falls under the FDA pregnancy risk category C and is generally not considered safe during pregnancy. The drug should only be considered when the potential maternal benefit justifies the potential risk to the fetus.</p>
          </list-item>
          <list-item>
            <p>Although quinidine concentrations in breast milk are lower than in maternal plasma, quinidine does pass into breast milk. Breastfeeding neonates can develop serum quinidine concentrations lower than those in the mother. Neonates may experience toxicity even with lower plasma quinidine levels.</p>
          </list-item>
          <list-item>
            <p>The anticholinergic activity of quinidine&#x000a0;can potentially exacerbate the symptoms of myasthenia gravis in patients. In addition, quinidine may interact with other drugs used to treat the disease.</p>
          </list-item>
          <list-item>
            <p>Caution is advised when using quinidine in patients with asthma and other allergic conditions, as these conditions can mask hypersensitivity reactions to the drug.</p>
          </list-item>
        </list>
        <p>
<bold>Box Warning</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Quinine should not be used to manage nocturnal leg cramps due to the risk of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS). A triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury characterizes HUS. TTP presents as a pentad of fever, neurologic dysfunction, microangiopathic hemolytic anemia, thrombocytopenia, and a high risk of chronic kidney disease.<xref ref-type="bibr" rid="article-28154.r26">[26]</xref><xref ref-type="bibr" rid="article-28154.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Due to the increased mortality risk, the ACC/AHA/HRS does not approve of using&#x000a0;quinidine to treat atrial fibrillation.<xref ref-type="bibr" rid="article-28154.r28">[28]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Safe Practice</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Quinidine can sometimes be confused with clonidine and quinine. For safer medication administration, it is recommended to use tall-man lettering.<xref ref-type="bibr" rid="article-28154.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Adjustment of dosages may be necessary for patients with hepatic and renal disorders.</p>
          </list-item>
          <list-item>
            <p>Caution should be exercised when administering quinidine with drugs known to prolong the QT interval, such as thiazide diuretics, ondansetron, opioids, fluoroquinolones, risperidone, sotalol, antihistamines, tricyclic antidepressants, macrolides (erythromycin), and selective serotonin reuptake inhibitors (SSRIs).<xref ref-type="bibr" rid="article-28154.r30">[30]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28154.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Routine EKG monitoring for QT interval and QRS changes and complete blood count (CBC), liver, and renal function testing should be conducted regularly when administering quinidine to patients via IV infusion or for an extended duration.<xref ref-type="bibr" rid="article-28154.r6">[6]</xref> Monitoring and correcting for electrolyte abnormalities known to cause QT prolongation, such as hypokalemia, hypomagnesemia, and hypocalcemia,&#x000a0;are essential. Using the Tisdale risk score can be a valuable strategy to screen for potential QT interval issues and help with risk mitigation.<xref ref-type="bibr" rid="article-28154.r30">[30]</xref></p>
      </sec>
      <sec id="article-28154.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Quinidine is widely known for its potential toxicity, leading to QT prolongation, and it can trigger TdP, a&#x000a0;life-threatening arrhythmia. As the condition can be fatal, it requires immediate management, including discontinuing the drug, closely monitoring cardiac and electrolyte levels (potassium and magnesium), and addressing any underlying hypoxia. Clinicians can effectively manage TdP by promptly administering magnesium sulfate and terminating prolonged episodes through electrical cardioversion. In refractory cases, isoproterenol or transvenous pacing may be the treatment options.&#x000a0;In addition, hypotension can be addressed with IV fluids, and norepinephrine might be required in refractory cases.<xref ref-type="bibr" rid="article-28154.r31">[31]</xref></p>
        <p>
<bold>Hepatoxicity</bold>
</p>
        <p>Chronic therapy with quinidine has been linked to acute hypersensitivity reactions, including hepatic involvement. The responses typically manifest within 1 to 2 weeks after treatment. Clinical features include fatigue, vomiting, muscle aches, arthralgia, and high fever. Blood testing at an early stage reveals elevated serum aminotransferase and alkaline phosphatase levels, along with mild jaundice, which may persist for a few days even after discontinuing quinidine. The pattern of serum enzyme elevations is typically cholestatic or mixed, characterized by an increase in alkaline phosphatase levels and mild jaundice.</p>
        <p>Clinical features of hypersensitivity are often characterized by arthralgia and fever. Liver biopsies typically reveal small epithelioid granulomas characteristic of systemic hypersensitivity reactions. As previously stated, hepatotoxicity occurs due to a hypersensitive reaction, and there is no indication of direct hepatotoxicity. To manage the situation, it is necessary to discontinue taking quinidine immediately. As hypersensitivity reactions are generally mild and self-resolving, corticosteroids should be avoided.<xref ref-type="bibr" rid="article-28154.r32">[32]</xref></p>
      </sec>
      <sec id="article-28154.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Quinidine, one of the oldest drugs for arrhythmia management, remains valuable in treating conditions like early repolarization syndrome, Brugada syndrome, idiopathic ventricular fibrillation, and specific infections such as <italic toggle="yes">P falciparum</italic> malaria. An interprofessional&#x000a0;team approach involving physicians, mid-level practitioners, nurses, cardiologists, rheumatologists, and pharmacists is essential to detect and manage potentially fatal drug toxicity effectively.</p>
        <p>The team of cardiologists is essential in administering quinidine therapy, as this drug is utilized as either an antiarrhythmic or proarrhythmic agent. Due to the potential of quinidine to cause a lupus-like syndrome, rheumatologists are involved in the treatment process. Meanwhile, infectious disease specialists also play an essential role in managing severe malaria cases. Nurses are critical in ensuring accurate drug administration and monitoring for any adverse effects, whereas pharmacists confirm the appropriate medication dosage.</p>
        <p>When initiating quinidine therapy, dosage adjustments may be necessary for neonates and older populations,those taking other medications&#x000a0;such as digoxin, as well as patients with CHF, a known history of QT interval prolongation, hepatic or renal dysfunction, and those taking other medications&#x000a0;such as digoxin. Cardiologists and intensivists provide inpatient consults, ICU care, and monitoring when hospitalization is necessary. The collective responsibilities underscore the importance of an interprofessional healthcare team approach for ensuring effective and safe therapy with quinidine.</p>
      </sec>
      <sec id="article-28154.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28154&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28154">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28154/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28154">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28154.s11">
        <title>References</title>
        <ref id="article-28154.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hanon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schweitzer</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Quinidine revisited.</article-title>
            <source>Am J Med</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>122</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-21</page-range>
            <pub-id pub-id-type="pmid">19249010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rehman</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zehri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thapa</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Quinine versus Artemether in the treatment of severe malaria.</article-title>
            <source>J Nepal Health Res Counc</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>23</issue>
            <fpage>17</fpage>
            <page-range>17-21</page-range>
            <pub-id pub-id-type="pmid">23787519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fralick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sacks</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kesselheim</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.</article-title>
            <source>JAMA Intern Med</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>179</volume>
            <issue>2</issue>
            <fpage>224</fpage>
            <page-range>224-230</page-range>
            <pub-id pub-id-type="pmid">30615021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Precision therapy with quinidine of KCNT1-related epileptic disorders: A systematic review.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>88</volume>
            <issue>12</issue>
            <fpage>5096</fpage>
            <page-range>5096-5112</page-range>
            <pub-id pub-id-type="pmid">35940594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Starmer</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics.</article-title>
            <source>Biophys J</source>
            <year>1984</year>
            <month>Jul</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-27</page-range>
            <pub-id pub-id-type="pmid">6331543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Khatib</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Callans</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Dickfeld</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Gillis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Matlock</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Myerburg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Sep</month>
            <day>25</day>
            <volume>138</volume>
            <issue>13</issue>
            <fpage>e272</fpage>
            <page-range>e272-e391</page-range>
            <pub-id pub-id-type="pmid">29084731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vitali Serdoz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rittger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Furlanello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bastian</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Quinidine-A legacy within the modern era of antiarrhythmic therapy.</article-title>
            <source>Pharmacol Res</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>144</volume>
            <fpage>257</fpage>
            <page-range>257-263</page-range>
            <pub-id pub-id-type="pmid">31026503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taggart</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Holyoak</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.</article-title>
            <source>Clin Ther</source>
            <year>1983</year>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>357</fpage>
            <page-range>357-64</page-range>
            <pub-id pub-id-type="pmid">6871920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <chapter-title>Quinidine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>1</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">30000148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roden</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Woosley</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Clinical features and basic mechanisms of quinidine-induced arrhythmias.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1986</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>1 Suppl A</issue>
            <fpage>73A</fpage>
            <page-range>73A-78A</page-range>
            <pub-id pub-id-type="pmid">2423573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benton</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Sale</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flockhart</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Woosley</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Greater quinidine-induced QTc interval prolongation in women.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>413</fpage>
            <page-range>413-8</page-range>
            <pub-id pub-id-type="pmid">10801251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ochs</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sonntag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Entry of quinidine into cerebrospinal fluid.</article-title>
            <source>Am Heart J</source>
            <year>1980</year>
            <month>Sep</month>
            <volume>100</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-6</page-range>
            <pub-id pub-id-type="pmid">7405805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000f8;rding</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feldt-Rasmussen</surname>
                <given-names>UF</given-names>
              </name>
            </person-group>
            <article-title>[Acute iridocyclitis with fever and liver involvement during quinidine therapy].</article-title>
            <source>Ugeskr Laeger</source>
            <year>1991</year>
            <month>Aug</month>
            <day>19</day>
            <volume>153</volume>
            <issue>34</issue>
            <fpage>2362</fpage>
            <page-range>2362-3</page-range>
            <pub-id pub-id-type="pmid">1897051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alloway</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Salata</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Quinidine-induced rheumatic syndromes.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>315</fpage>
            <page-range>315-22</page-range>
            <pub-id pub-id-type="pmid">7604299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fisher</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Visual disturbances associated with quinidine and quinine.</article-title>
            <source>Neurology</source>
            <year>1981</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>1569</fpage>
            <page-range>1569-71</page-range>
            <pub-id pub-id-type="pmid">7198212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gershwin</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced lupus erythematosus: incidence, management and prevention.</article-title>
            <source>Drug Saf</source>
            <year>2011</year>
            <month>May</month>
            <day>01</day>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>357</fpage>
            <page-range>357-74</page-range>
            <pub-id pub-id-type="pmid">21513360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Jick</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program.</article-title>
            <source>Prog Cardiovasc Dis</source>
            <year>1977</year>
            <season>Sep-Oct</season>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>151</fpage>
            <page-range>151-63</page-range>
            <pub-id pub-id-type="pmid">331400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leahey</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Bigger</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Reiffel</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>O'Connell</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Scaffidi</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Rottman</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Quinidine-digoxin interaction: time course and pharmacokinetics.</article-title>
            <source>Am J Cardiol</source>
            <year>1981</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>1141</fpage>
            <page-range>1141-6</page-range>
            <pub-id pub-id-type="pmid">7304462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hager</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Fenster</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mayersohn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perrier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Graves</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Digoxin-quinidine interaction Pharmacokinetic evaluation.</article-title>
            <source>N Engl J Med</source>
            <year>1979</year>
            <month>May</month>
            <day>31</day>
            <volume>300</volume>
            <issue>22</issue>
            <fpage>1238</fpage>
            <page-range>1238-41</page-range>
            <pub-id pub-id-type="pmid">431681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spinler</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kindwall</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Charland</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Possible inhibition of hepatic metabolism of quinidine by erythromycin.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1995</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <page-range>89-94</page-range>
            <pub-id pub-id-type="pmid">7828386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Data</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Nies</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Interaction of quinidine with anticonvulsant drugs.</article-title>
            <source>N Engl J Med</source>
            <year>1976</year>
            <month>Mar</month>
            <day>25</day>
            <volume>294</volume>
            <issue>13</issue>
            <fpage>699</fpage>
            <page-range>699-702</page-range>
            <pub-id pub-id-type="pmid">1250281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hardy</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Schentag</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance.</article-title>
            <source>Int J Clin Pharmacol Ther Toxicol</source>
            <year>1988</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>388</fpage>
            <page-range>388-91</page-range>
            <pub-id pub-id-type="pmid">3220613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burckart</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Marin-Garcia</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Quinidine dosage in children using population estimates.</article-title>
            <source>Pediatr Cardiol</source>
            <year>1986</year>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>269</fpage>
            <page-range>269-73</page-range>
            <pub-id pub-id-type="pmid">3725633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ochs</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Reduced quinidine clearance in elderly persons.</article-title>
            <source>Am J Cardiol</source>
            <year>1978</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>481</fpage>
            <page-range>481-5</page-range>
            <pub-id pub-id-type="pmid">356577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crouthamel</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>The effect of congestive heart failure on quinidine pharmacokinetics.</article-title>
            <source>Am Heart J</source>
            <year>1975</year>
            <month>Sep</month>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>335</fpage>
            <page-range>335-9</page-range>
            <pub-id pub-id-type="pmid">1163425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kojouri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vesely</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes.</article-title>
            <source>Ann Intern Med</source>
            <year>2001</year>
            <month>Dec</month>
            <day>18</day>
            <volume>135</volume>
            <issue>12</issue>
            <fpage>1047</fpage>
            <page-range>1047-51</page-range>
            <pub-id pub-id-type="pmid">11747383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brocklebank</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kavanagh</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Thrombotic Microangiopathy and the Kidney.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2018</year>
            <month>Feb</month>
            <day>07</day>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>300</fpage>
            <page-range>300-317</page-range>
            <pub-id pub-id-type="pmid">29042465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>January</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Furie</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.</article-title>
            <source>Circulation</source>
            <year>2019</year>
            <month>Jul</month>
            <day>09</day>
            <volume>140</volume>
            <issue>2</issue>
            <fpage>e125</fpage>
            <page-range>e125-e151</page-range>
            <pub-id pub-id-type="pmid">30686041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Salazar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Volk</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs.</article-title>
            <source>J Am Med Inform Assoc</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>872</fpage>
            <page-range>872-884</page-range>
            <pub-id pub-id-type="pmid">29800453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khatib</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sabir</surname>
                <given-names>FRN</given-names>
              </name>
              <name>
                <surname>Omari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pepper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tayebjee</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Managing drug-induced QT prolongation in clinical practice.</article-title>
            <source>Postgrad Med J</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>97</volume>
            <issue>1149</issue>
            <fpage>452</fpage>
            <page-range>452-458</page-range>
            <pub-id pub-id-type="pmid">33122341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatment of acquired QT prolongation and torsades de pointes.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>420</fpage>
            <page-range>420-7</page-range>
            <pub-id pub-id-type="pmid">26183037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28154.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <chapter-title>Quinidine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>5</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31644176</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
